Preclinical activity of anti-CCR7 immunotherapy in patients with high-risk chronic lymphocytic leukemia
C Cuesta-Mateos, J Loscertales, A Kreutzman… - Cancer Immunology …, 2015 - Springer
Chronic lymphocytic leukemia (CLL) with deletions of the p 53 locus on chromosome 17
and/or refractory to fludarabine chemoimmunotherapy remains a major clinical problem with …
and/or refractory to fludarabine chemoimmunotherapy remains a major clinical problem with …
Preclinical activity of anti-CCR7 immunotherapy in patients with high-risk chronic lymphocytic leukemia.
C Cuesta-Mateos, J Loscertales… - Cancer Immunology …, 2015 - search.ebscohost.com
Chronic lymphocytic leukemia (CLL) with deletions of the p53 locus on chromosome 17
and/or refractory to fludarabine chemoimmunotherapy remains a major clinical problem with …
and/or refractory to fludarabine chemoimmunotherapy remains a major clinical problem with …
[PDF][PDF] Preclinical activity of anti‑CCR7 immunotherapy in patients with high‑risk chronic lymphocytic leukemia
C Cuesta‑Mateos, J Loscertales, A Kreutzman… - 2015 - researchgate.net
Accepted: 14 February 2015© Springer-Verlag Berlin Heidelberg 2015 vitro activity was also
demonstrated in patients with a disease refractory to both fludarabine and alemtuzumab …
demonstrated in patients with a disease refractory to both fludarabine and alemtuzumab …
Preclinical activity of anti-CCR7 immunotherapy in patients with high-risk chronic lymphocytic leukemia
C Cuesta-Mateos, J Loscertales, A Kreutzman… - Cancer Immunology …, 2015 - infona.pl
Chronic lymphocytic leukemia (CLL) with deletions of the p53 locus on chromosome 17
and/or refractory to fludarabine chemoimmunotherapy remains a major clinical problem with …
and/or refractory to fludarabine chemoimmunotherapy remains a major clinical problem with …
[HTML][HTML] Preclinical activity of anti-CCR7 immunotherapy in patients with high-risk chronic lymphocytic leukemia
C Cuesta-Mateos, J Loscertales… - Cancer Immunology …, 2015 - ncbi.nlm.nih.gov
Chronic lymphocytic leukemia (CLL) with deletions of the p53 locus on chromosome 17
and/or refractory to fludarabine chemoimmunotherapy remains a major clinical problem with …
and/or refractory to fludarabine chemoimmunotherapy remains a major clinical problem with …
Preclinical activity of anti-CCR7 immunotherapy in patients with high-risk chronic lymphocytic leukemia.
C Cuesta-Mateos, J Loscertales… - Cancer Immunology …, 2015 - europepmc.org
Chronic lymphocytic leukemia (CLL) with deletions of the p53 locus on chromosome 17
and/or refractory to fludarabine chemoimmunotherapy remains a major clinical problem with …
and/or refractory to fludarabine chemoimmunotherapy remains a major clinical problem with …
Preclinical activity of anti-CCR7 immunotherapy in patients with high-risk chronic lymphocytic leukemia
C Cuesta-mateos, J Loscertales… - Cancer Immunology …, 2015 - search.proquest.com
Chronic lymphocytic leukemia (CLL) with deletions of the p53 locus on chromosome 17
and/or refractory to fludarabine chemoimmunotherapy remains a major clinical problem with …
and/or refractory to fludarabine chemoimmunotherapy remains a major clinical problem with …
Preclinical activity of anti-CCR7 immunotherapy in patients with high-risk chronic lymphocytic leukemia
C Cuesta-Mateos, J Loscertales… - Cancer …, 2015 - pubmed.ncbi.nlm.nih.gov
Chronic lymphocytic leukemia (CLL) with deletions of the p53 locus on chromosome 17
and/or refractory to fludarabine chemoimmunotherapy remains a major clinical problem with …
and/or refractory to fludarabine chemoimmunotherapy remains a major clinical problem with …
Preclinical activity of anti-CCR7 immunotherapy in patients with high-risk chronic lymphocytic leukemia.
C Cuesta-Mateos, J Loscertales… - Cancer Immunology …, 2015 - europepmc.org
Chronic lymphocytic leukemia (CLL) with deletions of the p53 locus on chromosome 17
and/or refractory to fludarabine chemoimmunotherapy remains a major clinical problem with …
and/or refractory to fludarabine chemoimmunotherapy remains a major clinical problem with …